In 2015, pharmaceutical companies continued to ignite mergers and acquisitions in the war, with less than 20 days of opening, and at least five pharmaceutical companies listed in the global market announced mergers and acquisitions.
Goal: A drug in research
Buyer: Pfizer
Seller: Redvax
Price: Unknown
Purpose: CMV vaccine
In 2015, Pfizer announced the acquisition of Redvax's controlling stake, further expanding its vaccine business. Redvax said that the integration of Redvax's assets with Pfizer's technology and resources can greatly advance the development of preclinical human cytomegalovirus (CMV) vaccines.
Redvax develops a large number of virus-like particles and other protein components, which play an important role in vaccine research and development. Pfizer believes that CMV vaccine is a huge market. CMV is a herpes virus that can infect 50-90% of adults. Most of them are asymptomatic.
Buyer: Gilead
Seller: Phenex Pharmaceuticals
Price: estimated at $470 million
Purpose: FXR Project
Recently, Gilead Science signed a definitive agreement to acquire the Phenex Pharmaceutical Farnesoid Derivative X Receptor (FXR) project, which includes small molecules for the treatment of liver diseases including nonalcoholic steatohepatitis (NASH). FXR agonist. Gilead plans to work with the Phenex R&D team to advance the FXR program to the clinical development phase as soon as possible.
Gilead Chief Scientific Officer Bischofberger said the deal represents an important opportunity for Gilead to accelerate the development of new treatment options for fibrotic liver disease.
Buyer: Roche
Seller: biotechnology company trophos
Price: 470 million euros
Objective: olesoxime for the treatment of spinal muscular atrophy
Roche recently acquired French trophos for 470 million euros. This is a privately held biotechnology company located in Marseille, France. Trophos has developed olesoxime and is currently investigating its role in the treatment of spinal muscular atrophy. Spinal muscular atrophy is a rare hereditary neuromuscular disease most commonly found in children. Phase 2 clinical trials have shown that olesoxime is effective in maintaining neuromuscular function and can reduce complications.
Roche said that the research and development of olesoxime will be further carried out based on the work of the trophos and the French Muscular Dystrophy Association.
Air Hose Reel,Mini Air Hose Reel,Air Compressor Hose Reel,Industrial Air Hose Reel
NINGBO QIKAI ENVIRONMENTAL TECHNOLOGY CO.,LTD , https://www.water-hose-reel.com